# Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

> **NCT04227106** · PHASE3 · COMPLETED · sponsor: **Abeona Therapeutics, Inc** · enrollment: 11 (actual)

## Conditions studied

- Epidermolysis Bullosa
- Recessive Dystrophic Epidermolysis Bullosa

## Interventions

- **BIOLOGICAL:** EB-101

## Key facts

- **NCT ID:** NCT04227106
- **Lead sponsor:** Abeona Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-10
- **Primary completion:** 2022-10-18
- **Final completion:** 2022-10-18
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2022-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04227106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04227106, "Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04227106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*